UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 CAREDX, INC. (Exact Name of Registrant as Specified in its Charter) Registrant's telephone number, including area code N/A (Former Name, or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy ...

Core Insights - CareDx (CDNA) shares increased by 11.2% to $24.91, following a significant trading volume, contrasting with a 5.2% decline over the past month [1] - The upcoming fourth-quarter 2024 financial results are anticipated to show approximately 30% year-over-year revenue growth, with testing services volume increasing by 14% [2] - The consensus EPS estimate for the quarter is $0.07, reflecting a year-over-year increase of 141.2%, with expected revenues of $85.5 million, up 30.4% from the previous year [3] Earnings and Revenue Expectations - Adjusted EBITDA is projected to be between $25 million and $26 million for the fourth quarter [2] - The consensus EPS estimate has been revised 13.2% higher in the last 30 days, indicating a positive trend that typically leads to price appreciation [4] Industry Context - CareDx is part of the Zacks Medical Services industry, which includes other companies like LifeMD, Inc. (LFMD), that saw a 5.5% increase in its last trading session [4] - LifeMD's EPS estimate remains unchanged at -$0.06, representing a 50% year-over-year change [5]

CareDx (CDNA) closed the last trading session at $23.10, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $32.86 indicates a 42.3% upside potential.The average comprises seven short-term price targets ranging from a low of $24 to a high of $40, with a standard deviation of $6.39. While the lowest estimate indicates an increase of 3.9% from the current price level, the m ...

Company Overview - CareDx (CDNA) is a notable stock within the Medical group, which consists of 1010 companies and currently ranks 3 in the Zacks Sector Rank [2] - CareDx has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook with a 36.9% increase in the consensus estimate for full-year earnings over the past quarter [3] Performance Comparison - Year-to-date, CareDx has returned approximately 6.7%, significantly outperforming the Medical sector's average return of -0.6% [4] - In comparison, DaVita HealthCare (DVA) has also outperformed the sector with a year-to-date return of 15.8% [4] Industry Context - CareDx operates within the Medical Services industry, which includes 59 companies and currently ranks 151 in the Zacks Industry Rank; this industry has seen an average loss of 6.7% this year, highlighting CareDx's superior performance [5] - DaVita HealthCare belongs to the Medical - Outpatient and Home Healthcare industry, which consists of 18 stocks and is ranked 69, with a year-to-date increase of 16.9% [6]

Core Insights - CareDx (CDNA) shares increased by 6.1% to close at $25.07, attributed to higher trading volume compared to typical sessions, with a 3.4% gain over the past four weeks [1] Financial Performance - CareDx is expected to report preliminary fourth-quarter 2024 revenues between $85 million and $86 million, reflecting a 30% year-over-year increase, surpassing the Zacks Consensus Estimate of 25.2% growth [2] - Testing service revenue is projected to rise nearly 35% year-over-year, driven by a 14% increase in volumes [2] - The company anticipates quarterly earnings of $0.07 per share, representing a year-over-year increase of 141.2%, with revenues expected to reach $82.12 million, up 25.2% from the previous year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for CareDx has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - CareDx currently holds a Zacks Rank of 3 (Hold), while another company in the medical services industry, Avantor, Inc. (AVTR), has a Zacks Rank of 4 (Sell) [4]

Group 1 - The article discusses the process of identifying potential investment opportunities for the "Bioreactor" growth portfolio within the Compounding Healthcare Investing Group [1] - The focus is on innovative companies that are developing breakthrough therapies and pharmaceuticals, particularly those with catalysts for potential acquisitions [3] - The investing group offers several model healthcare portfolios, a weekly newsletter, a daily watchlist, and a platform for dialogue and questions among members [4] Group 2 - The author has a beneficial long position in the shares of TMO and BIO, indicating a personal investment interest in these companies [1] - The article encourages readers to explore the subscription marketplace service, Compounding Healthcare, for more insights into investment methods and opportunities [2]

Group 1 - CareDx (CDNA) is currently outperforming its Medical sector peers with a year-to-date return of approximately 113.7%, compared to the sector average of 2.1% [4] - The Zacks Rank for CareDx is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions, with a 16.7% increase in the consensus estimate for full-year earnings over the past 90 days [3] - CareDx is part of the Medical Services industry, which has an average year-to-date loss of 5.4%, further highlighting CareDx's strong performance relative to its industry [5] Group 2 - Clover Health Investments, Corp. (CLOV) has also shown strong performance with a year-to-date return of 260.3%, and it holds a Zacks Rank of 2 (Buy) with a 7.7% increase in the consensus EPS estimate over the past three months [4][5] - The Medical sector consists of 1025 individual stocks and currently holds a Zacks Sector Rank of 3, indicating a moderate strength among its groups [2] - The Medical Services industry, which includes CareDx, ranks 138 in the Zacks Industry Rank, while the Medical Info Systems industry, which includes Clover Health, ranks 34 [5][6]

Core Viewpoint - CareDx (CDNA) shows potential for significant upside, with a mean price target of $34.67 indicating a 49.9% increase from the current price of $23.13 [1] Price Targets - The average price target consists of six estimates ranging from a low of $28 to a high of $40, with a standard deviation of $4.97, suggesting a consensus among analysts [2] - The lowest estimate indicates a 21.1% increase, while the highest suggests a 72.9% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on CDNA's ability to report better earnings than previously predicted, which supports the expectation of stock upside [4] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 15.7%, with three estimates moving higher and no negative revisions [10] Zacks Rank - CDNA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11] Earnings Estimate Revisions - There is a strong correlation between trends in earnings estimate revisions and near-term stock price movements, suggesting that the positive revisions could lead to stock price increases [9]

CareDx (CDNA) has been on a downward spiral lately with significant selling pressure. After declining 12% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is over ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. CareDx (CDNA) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.CareDx is a member of the Medical sector. This group includes 1024 individual stocks and c ...